Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Cijeli opis

Bibliografski detalji

Glavni autori:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2017-06-01
Serija:	Blood Advances
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!